Inhibikase Therapeutics (IKT) Retained Earnings (2020 - 2026)
Inhibikase Therapeutics (IKT) reported Retained Earnings of -$159.1 million for Q1 2026, down 47.18% year-over-year from -$301.2 million in Q1 2025, and down 729849.56% quarter-over-quarter from $21802.0 in Q4 2025.
Inhibikase Therapeutics (IKT) Retained Earnings (2020 - 2026) Analysis & Trends
Inhibikase Therapeutics (IKT) has 7 years of Retained Earnings data on file, last reported at -$159.1 million in Q1 2026.
- Retained Earnings for Q1 2026 came in at -$159.1 million, down 47.18% year-over-year; the trailing twelve-month figure through Mar 2026 was -$159.1 million (down 47.18% YoY), and the FY2025 annual result was $21802.0, up 100.02% from the prior year.
- Retained Earnings retreated to -$159.1 million in Q1 2026 per IKT's latest filing, from $21802.0 in the prior quarter.
- Over five years, Retained Earnings peaked at $165822.0 in Q1 2023 and troughed at -$159.1 million in Q1 2026.
- A 5-year average of -$43.3 million and a median of -$34.5 million in 2022 frame the typical range for Retained Earnings.
- On a YoY basis, Retained Earnings climbed as much as 1326.57% in 2024 and fell as far as 10766418.24% in 2024.
- A 5-year view of Retained Earnings shows it stood at -$47.9 million in 2022, then surged by 100.0% to $877.0 in 2023, then tumbled by 10766418.24% to -$94.4 million in 2024, then jumped by 100.02% to $21802.0 in 2025, then slumped by 729849.56% to -$159.1 million in 2026.
- Business Quant data shows IKT's Retained Earnings at -$159.1 million in Q1 2026, $21802.0 in Q4 2025, and -$4189.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | -153.89 Mn |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -211.85 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 1.00 Bn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -279.00 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | 130.89 Mn |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | -1.88 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 14.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -838.07 Mn |
| 10 | Inhibikase Therapeutics | 285.17 Mn | 114.80 Mn | - | -159.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -159.10 Mn |
| Dec 31, 2025 | 21,802.00 |
| Sep 30, 2025 | -4,189.00 |
| Jun 30, 2025 | -118.01 Mn |
| Mar 31, 2025 | -108.10 Mn |
| Dec 31, 2024 | -94.42 Mn |
| Sep 30, 2024 | 1,754.00 |
| Jun 30, 2024 | -76.51 Mn |
| Mar 31, 2024 | -1,800.00 |
| Dec 31, 2023 | 877.00 |
| Sep 30, 2023 | -143.00 |
| Jun 30, 2023 | -58.13 Mn |
| Mar 31, 2023 | 165,822.00 |
| Dec 31, 2022 | -47.87 Mn |
| Sep 30, 2022 | 26,828.00 |
| Jun 30, 2022 | -39.10 Mn |
| Mar 31, 2022 | -34.46 Mn |
| Dec 31, 2021 | -29.82 Mn |
| Sep 30, 2021 | -24.78 Mn |
| Jun 30, 2021 | -20.30 Mn |